Biofortuna (Deeside UK), a specialist contract development and manufacturing partner to the IVD and point of care testing sectors, has more than doubled its manufacturing capacity following its relocation to new state-of-the-art facilities in Deeside, North Wales. The purpose-built facilities have been designed by the Company to provide the most efficient and modern manufacturing laboratories from which to meet the evolving needs of the world’s leading IVD and point of care businesses...
Biofortuna is expanding its IVD service portfolio to provide a greater focus on immunoassay design, development and manufacture.
The company has made a significant investment in its production capabilities to include plate coating, washing, drying and quality control, creating an exceptional manufacturing suite for immunoassay kits. Biofortuna already has extensive experience in immunoassay development, and this expansion has been driven by the success of current customer projects and increasing demand from the market....
Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has successfully achieved key milestones in the development of its new blood group genotyping product family – ReadyPlex™.
This breakthrough has released the second tranche of its 2015 funding – totalling £1.5m – which will be used for final development and commercialisation of this innovative product line. The ReadyPlex range is aimed at the transfusion market, and will offer rapid genomic analysis of erythrocyte blood groups, human platelet antigens (HPAs), human neutrophil antigens (HNAs) and coagulation polymorphisms...
Diagnostics company Biofortuna will mark the 2015 AACC Annual Meeting and Clinical Lab Expo in Atlanta, USA, with the launch of a broader portfolio of custom manufacturing and development services for the IVD market.
World-renowned for its lyophilisation services and molecular diagnostic products, Biofortuna has developed a new internal infrastructure, creating distinct products and services divisions and giving the company a strong focus for growth and efficiency. The breadth of the company’s portfolio of IVD manufacturing and development services has expanded to include manufacturing, dispensing, kitting, labelling, capping, as well as design and development of...
UK based molecular diagnostics company Biofortuna has appointed a new chairman to lead the next phase of growth.
Life sciences expert Ian Johnson will take on the role at Biofortuna with previous chairman Mark Hurley remaining on the board as a non-executive director. Biofortuna, based in the Wirral, specialises in proprietary freeze dried diagnostics and contract services. It recently announced a £1.5m funding round for the company to further develop its diagnostic assays and invest in its freeze drying production capability. Former chairman Hurley said: “Over the years I have thoroughly...
Biofortuna Ltd, the UK based molecular diagnostics company specialising in its proprietary freeze dried diagnostics and contract services, announces raising £1.5m in its latest funding round.
The £1.5m funding was supported by all the company’s current investors; Foresight VCTs, Catapult Ventures, Enterprise Ventures, Merseyside Special Investment Fund, private investors and management. The new funding is for Biofortuna to develop a portfolio of new molecular diagnostic assays with the aim of providing easy to use, one step diagnostics that address complex genotyping issues. In addition, the company will...
Biofortuna, a UK based molecular diagnostics company with proprietary freeze drying (lyophilizing) technology, has received FDA 510K clearance for its line of SSPGoTMÂ HLA PCR kits.
The SSPGo HLA Typing Kits are qualitative DNA-based kits for determining HLA alleles in low to intermediate resolution. The kits are designed for transplantation genotyping and identification of genes which may be associated with various genetic conditions. In 2011, Biofortuna announced an exclusive global distribution agreement with Abbott for its SSPGoTM kits. Until now, the kits were CE marked and only distributed in Europe and Asia Pacific. Now with FDA clearance, kits will be available in early 2014 in the United States. Dr Simon Douglas, CEO of Biofortuna stated “I am delighted that Biofortuna has received FDA clearance of its SSPGoTM kits...
Biofortuna, a UK based molecular diagnostics company with a proprietary stabilisation technology for molecular reagents, is expanding its custom service and manufacturing business with a £1.3m investment.
The new funds will enable the business to expand its freeze drying analysis and manufacturing capability to support both its custom service clients and the USA launch of its SSPGo HLA range of products through Abbott Molecular. The funding was supported by all of the company’s current investors; the Foresight Group (UK), EV Group, Catapult Venture Managers, Merseyside Special Investment Fund, private investors and management...
Biofortuna Extends Its Exclusive Distribution Agreement with Abbott to Cover All Global Territories
Apr 25, 2012Biofortuna Ltd, a UK-based molecular diagnostics company, today announced they have extended its exclusive distribution agreement with Abbott, for its SSPGoTM range of freeze dried HLA typing kits, to now include France, Spain, Portugal and the Benelux countries. Under terms of the agreement, first announced in April, 2011, Abbott now obtains exclusive rights to distribute the range of SSPGoTM products, Verdict interpretation software, as well as kit updates and improvements, in all global territories...
Biofortuna heats up the PCR market with the world’s first freeze-dried solution
Oct 26, 2010UK-based molecular diagnostics company Biofortuna Limited has unveiled the world's first complete freeze-dried HLA PCR kit in a move set to transform the transplantation market. The award-winning firm, led by internationally renowned HLA molecular immunologist Dr Mike Bunce, is revolutionising clinical testing methods with its proprietary freeze-dried ‘SSP Go' technology.
Biofortuna (Deeside UK), a specialist contract development and manufacturing partner to the IVD and point of care testing sectors, has more than doubled its manufacturing capacity following its relocation to new state-of-the-art facilities in Deeside, North Wales. The purpose-built facilities have been designed by the Company to provide the most efficient and modern manufacturing laboratories from which to meet the evolving needs of the world’s leading IVD and point of care businesses...
The company has made a significant investment in its production capabilities to include plate coating, washing, drying and quality control, creating an exceptional manufacturing suite for immunoassay kits. Biofortuna already has extensive experience in immunoassay development, and this expansion has been driven by the success of current customer projects and increasing demand from the market....
This breakthrough has released the second tranche of its 2015 funding – totalling £1.5m – which will be used for final development and commercialisation of this innovative product line. The ReadyPlex range is aimed at the transfusion market, and will offer rapid genomic analysis of erythrocyte blood groups, human platelet antigens (HPAs), human neutrophil antigens (HNAs) and coagulation polymorphisms...
Life sciences expert Ian Johnson will take on the role at Biofortuna with previous chairman Mark Hurley remaining on the board as a non-executive director. Biofortuna, based in the Wirral, specialises in proprietary freeze dried diagnostics and contract services. It recently announced a £1.5m funding round for the company to further develop its diagnostic assays and invest in its freeze drying production capability. Former chairman Hurley said: “Over the years I have thoroughly...
Biofortuna Ltd, a UK-based molecular diagnostics company, today announced that they have signed an exclusive distribution agreement with Abbott's molecular diagnostics business, whereby Biofortuna will design, develop and manufacture a range of freeze-dried HLA-typing kits called SSPGo. Financial terms have not been disclosed...